Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

eptember 30, 2009 general and administrative expenses increased to $2.7 million from $2.2 million in 2008. The increase in 2009 was primarily due to increased employee expenses and increased costs associated with operating as a public company.

The net loss for the third quarter increased to $2.4 million from $4.6 million in income in 2008. For the nine months ended September 30, 2009 the net loss increased to $9.4 million from $0.8 million in income in 2008. The net income recognized in both 2008 periods was primarily due to the impact of an extraordinary gain on the reverse takeover of Sonus and a reversal of tax expense associated with the change in capital structure of OncoGenex Technologies, both non-cash items.

The third quarter and nine months ended September 30, 2008 also included $0.4 million and $2.0 million, respectively, in preferred share accretion, a non-cash item, which did not recur in the third quarter or nine months ended September 30, 2009, as subsequent to the reverse takeover there are no preferred shares outstanding.

The Company had $12.5 million in cash, cash equivalents and short-term investments as of September 30, 2009, compared to $12.4 million in cash, cash equivalents and short-term investments as of December 31, 2008.

The Company had 6,034,959 shares outstanding as of November 1, 2009. The Company believes that its cash, cash equivalents and short-term investments will be sufficient to fund its currently planned operations through at least the third quarter of 2010, including:

    -   completing partnering discussions related to OGX-011;
    -   completing follow-up monitoring visits related to completed phase 2
        clinical trials of OGX-011;
    -   completing follow-up monitoring visits related to the Phase 1
        clinical trial evaluating OGX-427 as a monotherapy in patients with
        solid tumors and continuing evaluation of OGX-427 in combination with
        docetaxe
'/>"/>
SOURCE  OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... In a sneak preview of ... present technologies with applications in multiple and diverse ... Optics and Photonics symposium in San Diego, ... international society for optics and photonics , the ... and technology meeting in North America, with approximately ...
(Date:5/24/2013)... Many factors impact tissues targeting such as ... at the blood-tissue barrier. Even when tissue disposition is ... the tissue rather than the total tissue concentration. , ... to guide lead optimization, predict in vivo activity in ... may impact the likely human clinical dose. , In ...
(Date:5/23/2013)... day, their baby stopped breathing, his collapsed bronchus blocking ... and Bryan Gionfriddo watched helplessly, just praying that somehow ... doctors said he had a good chance of not ... now 20-month-old son, Kaiba. "At that point, we were ... and run with it." , They found hope at ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... (Pink Sheets: MNCN), a global health company that develops ... the agricultural and consumer markets, announced today that it ... LLC (MPC).Mach One acquired 100% of the LLC interests ... stock at a conversion price of $0.50 cents per ...
... CAMBRIDGE, Massachusetts, February 20, Shire plc (LSE: SHP, ... company, announced today that it has officially,opened a ... Soh Fujiwara as,Managing Director for Japanese operations. , ... Shinkujuku Ward, Tokyo, will serve as the base ...
... ImQuest Life Sciences presented important new results on ... inhibitors of HIV-1 at the 16th Conference on ... Montreal. Presentations focused on the results of IND-directed ... efficacy and formulation of IQP-0528 as a topical ...
Cached Biology Technology:Mach One Closes on Acquisition of Biopharmaceutical Design & Engineering Firm 2Shire Announces Opening of Office in Japan 2Shire Announces Opening of Office in Japan 3ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs 2ImQuest Presentations at CROI Report Significant Advances in Therapeutic and Microbicide Product Development Programs 3
(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/24/2013)... A conference of 500 leading water scientists from around ... major reforms, "in the short span of one or ... on Earth will be living under the handicap of ... resource for which there is no substitute. This handicap ... , The scientists bluntly pointed to chronic underlying problems ...
(Date:5/23/2013)... to be the world,s most popular fruit, can be ... with purple GM varieties. , "Working with GM ... the addition of a specific compound, allows us to ... Professor Cathie Martin from the John Innes Centre. , ... better flavour, health and shelf life characteristics because even ...
Breaking Biology News(10 mins):Please do try this at home 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 2A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 3A majority on Earth face severe self-inflicted water woes within 2 generations: Scientists 4The world's favorite fruit only better-tasting and longer-lasting 2
... The American Dietetic Association welcomes a report issued Wednesday, ... school meal programs to adopt standards that increase the ... to schoolchildren. "The IOM,s positive and progressive recommendations ... American Dietetic Association has been making for a number ...
... Ministry of Defence (MINDEF) and the Nanyang Technological University ... to strengthen Singapore,s defence science and technology research and ... intent by inking a Memorandum of Understanding (MOU) at ... governs the setting up of the Temasek Research Fellowship ...
... cancer drug will help an individual patient: only around one ... Researchers at the Heinz Nixdorf Chair for Medical Electronics at ... process for cancer drugs. With the help of microchips, they ... will react to a given drug. This chip could help ...
Cached Biology News:American Dietetic Association supports IOM recommendations on school meal programs 2American Dietetic Association supports IOM recommendations on school meal programs 3MINDEF, NTU join hands to boost Singapore's defense R&D capabilities 2Sensor biochips could aid in cancer diagnosis and treatment 2Sensor biochips could aid in cancer diagnosis and treatment 3
anti-Yan 8B12H9...
...
... the formation of phosphodiester bonds in the ... 3' hydroxyl and 5' phosphate termini. The ... which can be performed in 5 minutes ... for this enzyme. A T4 DNA ...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Biology Products: